Title page
Title: International expansion of a novel SARS-CoV-2 mutant
Authors: Minjin Wang, MD

- 4 Mengjiao Li, MD
- 5 Ruotong Ren, PhD
- 6 Andreas Bråve, PhD
- 7 Sylvie van der Werf, PhD
- 8 En-Qiang Chen, PhD
- 9 Zhiyong Zong, PhD
- 10 Weimin Li, PhD
- 11 Binwu Ying, PhD
- 12 Minjin Wang, Mengjiao Li, Ruotong Ren contributed equally to this letter.
- 13 **Author Affiliations:**
- 14 Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu,
- 15 China (Minjin Wang, Mengjiao Li, Binwu Ying).
- 16 Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, and Genskey
- 17 Biotechnology Co., Ltd., Beijing, China (Ruotong Ren).
- Department of microbiology, Public Health Agency of Sweden (Andreas Bråve).
- 19 Department of Virology, Molecular Genetics of RNA Viruses unit, CNRS UMR-3569,
- 20 University of Paris, National Reference Center for Respiratory Viruses Institut Pasteur (Sylvie
- van der Werf).
- 22 Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China
- 23 (En-Qiang Chen)
- 24 Department of Infection Control and Center of Infectious Diseases, West China Hospital of
- 25 Sichuan University, Chengdu, China (Zhiyong Zong)
- 26 Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan
- 27 University, Chengdu, China (Weimin Li)

29 Corresponding author:

28

30 Binwu Ying, PhD, Department of Laboratory Medicine, West China Hospital of Sichuan

- 31 University, Chengdu, China.
- 32 Email: <u>binwuying@126.com</u>, Tel: (0086)85423559
- 33 Address: Number 37 Guoxue Alley in the wuhou District, Chengdu, Sichuan, China

34

- 36 TO THE EDITOR:
- 37 SARS-CoV-2 has inevitably mutated during its pandemic spread¹ to cause
- unpredictable effects on COVID-19 and complicate epidemic control efforts. Here we
- 39 report that a novel SARS-CoV-2 mutation appears to be spreading worldwide, which
- 40 deserves close attention.
- 41 We detected 95 SARS-CoV-2 samples from Sichuan Province of China using next
- 42 generation sequencing and acquired 13 whole genomes sequences, which were
- analyzed for sequence variation and evolution against 199 SARS-CoV-2 genomes
- publicly released in the GISAID EpiFluTM database (https://www.gisaid.org/) and 7
- 45 genomes download from NGDC database (https://bigd.big.ac.cn/ncov). This study was
- 46 approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan
- 47 University (reference no. 193, 2020) and written informed consent was obtained from all
- 48 patients.
- 49 Based on 10 high frequency mutations (mutant allele frequency >5%), these
- 50 SARS-CoV-2 genomes can be classified into 5 main groups: original stain 1 and 4
- variants with different mutations groups and clustering. The most common variants
- 52 (Figure A, Group 1) exhibited both a missense mutation (ORF8:c.251tTa>tCa; present
- in 31.58% of the isolates) and a synonymous mutation (orf1ab:c.8517agC>agT; found
- in 30.62% of the isolates), suggesting a possible linkage between these two sites. Also,
- 55 3 subgroups were evolved in the main Group 1 by other 3 mutations. Group 2 was
- clustered together with 3 mutants including missense variant S: c.1841gAt>gGt,
- 57 orflab upstream gene variant and synonymous_variant orflab: c.2772ttC>ttT. Group
- 58 3 viral isolates were much less frequent (11.48%) and characterized by a missense
- 59 mutation (orf1ab:c.10818ttG>ttT). Group 4 viral isolates contained a novel missense
- 60 mutation (ORF3a:c.752gGt>gTt) first found in a Chinese family. Notably, however,
- 61 Group 4 viral isolates were most frequently found outside mainland China (23.28%;
- 62 27/116; p<0.01 by Fisher's exact test). Additionally, Group 2 and Group 4 showed
- obvious aggregation in non-Chinese countries and regions.
- The family in which the Group 4 variant was first observed in China (an older female

65 and two young family members) returned to their hometown in Sichuan from Wuhan 66 on January 20, 2020. By January 23, the mother had a fever and cough, and her two 67 children developed these symptoms in the following days. Nucleic acid assays performed on their throat swabs tested positive for SARS-CoV-2 on January 25. None 68 of these individuals traveled outside of China between the start of the COVID-19 69 epidemic and their return to Sichuan, but there the Group 4 variant first observed in 70 71 this family has now demonstrated global dissemination. We performed a timeline analysis using the sample collection dates reported in the 72 GISAID EpiFluTM database, and found that individuals infected with SARS-CoV-2 73 strain containing the Group 4 ORF3a mutant had reached the West Coast of the 74 United States (Orange County, California) by January 22, 2020 at the latest. 75 Immediately afterwards, and preceding or at nearly the same time as first Group 4 76 cases in Sichuan, additional isolates (Figure B) of this strain were reported in China 77 (Taiwan), France (Paris), and Australia (Sydney and Clayton). According to the 78 official records, these individuals either traveled from Wuhan, or traveled 79 internationally prior to their disease onset. Group 4 ORF3a mutants were 80 81 subsequently found in several other countries, including Singapore, South Korea, the 82 United Kingdom and Italy. It should be noted that this mutant virus strain appears to be the most prevalent form of SARS-COV-2 in France, Italy, Brazil, and Singapore 83 (Figure C). 84 Virus genome data from France indicate that SARS-CoV-2 strains carrying 85 ORF3a:c.752gGt>gTt often have a S:c.1099Gtc>Ttc mutation in their S gene, which 86 interacts with ACE2 to mediate viral entry into its host cells³, and is regarded as a 87 critical factor for viral transmission and virulence^{4, 5}. It is not clear if this mutation 88 89 enhances host cell entry but this information would be of great importance in assessing the potential for increased virulence of Group 4 SARS-CoV-2 strains 90 carrying this mutation. It is also not known how common this mutation is in Group 4 91 viral isolates from different geographical regions. Given the prevalence of Group 4 92 isolates in multiple countries, including France, Italy and South Korea, which is 93 experiencing a rapidly growing epidemic, this information should be of significant 94

- 95 interest.
- At present, the SARS-CoV-2 epidemic in China seems to be diminishing in response
- 97 to control efforts, but the rapid global spread of this new virus, and its mutants, has
- 98 become a major health concern. Very little is known about how rapidly the
- 99 SARS-CoV-2 genome mutates and how this affects transmission or disease severity.
- 100 Better understanding of these factors should be useful in efforts to curtail the global
- and regional spread of this virus.

102

- 103 **Conflict of Interest Disclosures:** None reported.
- 104 Funding/Support: This study was funded by Science & Technology Department of Sichuan
- 105 Province (Grant number: 2020YFS0004) and West China Hospital of Sichuan University
- 106 (Grant number: HX-2019-nCoV-066).
- 107 Additional Contributions: We thank Dr Wan Xiong for polishing the manuscript language.
- We also thank Shuo Guo and Yanbing Zhou for collecting literature.

109

110 **Reference**:

- 11 1. www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
- 112 2. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data -
- from vision to reality[J]. Euro surveillance: bulletin Europeen sur les maladies
- transmissibles = European communicable disease bulletin. 2017,22(13).
- doi:org/10.2807/1560-7917.es.2017.22.13.30494
- 116 3. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor
- usage for SARS-CoV-2 and other lineage B betacoronaviruses[J]. Nature
- microbiology. 2020. doi:org/10.1038/s41564-020-0688-y
- 4. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining 'host jump' of
- 120 coronaviruses SARS-CoV, MERS-CoV, and beyond[J]. Trends in microbiology.
- 2015,23(8):468-478. doi:org/10.1016/j.tim.2015.06.003
- 5. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue

- distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first
- step in understanding SARS pathogenesis[J]. The Journal of pathology.
- 2004,203(2):631-637. doi:org/10.1002/path.1570

126

127

- 128 Figure legend:
- Figure: Maximum likelihood tree based on the whole genome sequences of 221
- 130 viral strains.
- A) 199 high quality genomes were collected from GISAID EpiFluTM database,
- including 1 Rhinolophus affinis isolate, 6 Manis javanica isolates and 2 environmental
- isolates. 22 additional genomes were collected from other resource, including 7
- genomes from NGDC (https://bigd.big.ac.cn/ncov), 13 genomes from WCH.
- SARS-CoV (NC_004718.3) and MERS-CoV (NC_019843.3) genomes sequence
- were downloaded from NCBI RefSeq database. MAFFT (version 7.543) was used for
- sequence alignment, and PhyML (version 3.0) was used to construct the evolutionary
- tree. Variation information of human SARS-CoV-2 genome was derived from NGDC.
- 139 Mutations of 13 WCH genomes were analyzed using NGDC online tools
- 140 (https://bigd.big.ac.cn/ncov/tool/variation-identify).
- B) Location and collection time of ORF3a:c.752gGt>gTt variant genomes.
- 142 C) Composition of variant and non-variant genomes of ORF3a:c.752gGt>gTt in
- 143 different countries.

